Background: Protein S (PS) deficiency is a risk factor for adverse pregnancy outcomes
| INTRODUCTION

Protein S (PS) is a vitamin K-dependent glycoprotein that functions
as a cofactor to an anticoagulant serine protease, activated protein C (APC), and is an important regulator of blood coagulation. 1 Recently, many studies have suggested associations between adverse pregnancy outcome and PS deficiency. [2] [3] [4] [5] [6] Rey et al. performed a metaanalysis and reported that PS deficiency was associated with recurrent pregnancy loss and fetal loss after 22 weeks. 2 Robertson et al. reported in a systematic review that PS deficiency was associated with late fetal loss. 3 Some studies have suggested that the presence of anti-PS autoantibodies (anti-PS) leads to an acquired PS deficiency. 7, 8 Reports revealed low free PS levels in numerous patients with human immunodeficiency virus infection and an overall 28.6% anti-PS positivity with higher incidence in patients with PS levels of <50%. 7 D'Angelo et al. described a type of acquired PS deficiency associated with a circulating antibody against PS in a child suffering from severe thromboembolic disease while recovering from chickenpox. 8 They suggested that low PS antigen levels may have resulted from the rapid clearance of the circulating immune complex. In addition, they reported that the antibody did not show direct inhibitory effect on PS activity, which indicated that the interaction with a PS epitope(s) was not involved in the APC cofactor activity expression.
Consistent with the study, Morange et al. reported no evidence of PS activity inhibition by anti-PS. 9 In contrast, Sorice et al. demonstrated the possibility of PS activity inhibition by anti-PS. 10 Thus, existing literature fails to clarify whether anti-PS affects PS activity or determines the sites recognized by anti-PS.
Mature PS has a modular structure consisting of a γ-carboxyglutamic acid (Gla) domain, a thrombin-sensitive region (TSR), four epidermal growth factor (EGF)-like domains (EGF1-4), and a sex hormone-binding globulin-like domain containing two laminin
G-like-domain-like repeats (LGR).
The amino-terminal Gla domain confers the high-affinity interaction of PS with negatively charged phospholipid surfaces that is essential for APC-dependent functions of PS. 11, 12 TSR and EGF1 contribute to functionally crucial interactions of PS with APC. [13] [14] [15] Indeed, a three-dimensional structural model of the
Gla, TSR, and EGF1 domains of PS indicates an interaction between
the Gla domain and the membrane, which makes the other two domains available for interaction with the membrane-bound APC. 15 Additionally, other EGF-like domains appear to be involved in the APC cofactor function of PS. A recent report has indicated that EGF2 plays a role in the APC cofactor function of PS because of the resultant loss of function on replacing or deleting it. 16 Perhaps, EGF4 of PS is crucial for keeping EGF1 in optimal alignment for interacting with APC, 17 even though an unaided recombinant EGF4 has been unsuccessful in exhibiting APC cofactor activity in a clotting assay.
18
LGR is also involved in APC cofactor function, as indicated by the recent identification of the factor Va-binding site in the second LGR. 19 In the present study, we used PS treated with thrombin or lysyl endopeptidase, recombinant EGF, and polyclonal antibodies to EGF for inhibition and direct-binding for identifying anti-PS antigenic binding sites in patients with recurrent pregnancy loss. antibodies. In this epitope mapping study, we used blood samples from patients with recurrent pregnancy loss who had a high-titer anti-PS and whose sample volume was sufficient to do further examination.
| MATERIALS AND METHODS
| Patients
We also recruited 56 healthy non-pregnant female volunteers who had no history of miscarriage. Among them, four women (7.1%) were seropositive for anti-PS. We collected blood samples in non-activating plastic tubes with 3.2% trisodium citrate (9:1 v/v). After centrifugation, plasma aliquots were instantly stored at −60°C until further use.
All participants gave informed consent, and the study protocol was approved by the local ethics review committee. 
| Materials
| IgG purification from plasma
IgGs were purified from plasma by protein G-Agarose (Protein Ark Ltd, Sheffield, UK) chromatography following the manufacturer's recommendations.
| Dose-dependent binding of anti-PS to PS in an immunoblot assay
We performed sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS-PAGE) using 10% polyacrylamide gel. PS was prepared in non-reducing forms. Increasing concentrations (5 μL of 7.5, 15, 30, 60, 120 μg mL −1 solution) of PS were applied to each lane. Furthermore, it was transferred to polyvinylidene difluoride (PVDF) membrane for 20 min at 0.1 A; 1% BSA in TBS at pH 7.3. was used to block membranes for 1.5 hour. PS was incubated with purified IgG from anti-PS-positive patient plasma for 2 hour followed by three washes with 0.05% Tween 20/TBS. Additionally, we exposed the membrane to horseradish peroxidase-conjugated polyclonal antibodies to human IgG for 1 hour followed by washing as mentioned above. Then, immunobands were developed using 3,3′,5,5′-tetramethylbenzidine.
We performed SDS-PAGE using 10% polyacrylamide gel. PS was prepared in non-reducing forms. PS ( ) of purified IgG from anti-PSpositive patient plasma as described above.
| Cleavage of PS by thrombin
For the preparation of Gla-domain free PS, PS was incubated with thrombin at 37°C for 2 h. Then, we added dithiothreitol (DTT) to the thrombin-treated PS and vortexed and boiled the mixture at 100°C 
| Proteolysis of PS
For the preparation of fragments of EGF-like domains in PS, PS was incubated with high concentrations (30% or 60%) of lysyl endopeptidase (cleaves COOH-terminal of lysines) at 37°C for 1 hour in the presence of Ca 2+ (2 mM).
| Effects of Ca 2+ in immunoblot for anti-PS
We performed SDS-PAGE using 10% polyacrylamide gel. PS was pre- Additionally, we exposed the membrane to horseradish peroxidaseconjugated polyclonal antibodies to human IgM for 1 h followed by washing as mentioned above. Then, immunobands were developed using 3,3',5,5'-tetramethylbenzidine.
| RESULTS
| Dose-dependent binding of anti-PS to PS in ELISA
PS was coated onto microtiter plate wells in increasing concentrations ). We then applied anti-PS-positive patient plasma (X) or normal control plasma
(1:50) followed by an alkaline phosphatase-conjugated secondary antibody. The absorption was assessed at 405 nm. Figure 1A shows the concentration-dependent binding of anti-PS to PS.
PS (50 μL of 5 μg mL −1 solution) was coated on microtiter plate wells. We then applied several dilutions (1:3,200, 1:1600, 1:800, 1:400, 1:200, 1:100, and 1:50) of anti-PS-positive patient plasma (X) or normal control plasma followed by an alkaline phosphatase-conjugated secondary antibody. The absorption was assessed at 405 nm. Figure 1B shows the concentration-dependent binding of anti-PS to PS.
| Dose-dependent binding of anti-PS to PS in an immunoblot assay
Increasing concentrations (5 μL of 7.5, 15, 30, 60, 120 μg mL −1 solution)
of PS were applied to each lane. After transferring to PVDF membranes, membranes were incubated with purified IgG from anti-PS-positive patient or normal control and immunoblotting was performed. Figure 2A shows the concentration-dependent binding of anti-PS to PS.
PS ( ) of purified IgG from anti-PSpositive patient or normal control and immunoblotting was performed. Figure 2B shows the concentration-dependent binding of anti-PS to PS.
| Binding of anti-PS to Gla-domain free PS
Thrombin-treated PS or PS was subjected to SDS-PAGE under reducing conditions. We then transferred the slab gel contents to PVDF membranes and immunoblotted the contents with anti-PS-positive patient plasmas. Figure 3 shows the binding of anti-PS to Gla-domain free PS. Intact PS should show a single band of 86 kDa. However, in this study, two bands were seen, one of 86 kDa corresponding to PS and that of approximately 80 kDa corresponding to Gla-domain free PS. It was probably due to contamination of thrombin. Indeed, the same two bands were stained with Coomassie Brilliant Blue (data not shown).
| Binding of anti-PS to EGF-like domains
PS incubated with lysyl endopeptidase was subjected to SDS-PAGE under non-reducing conditions. We then transferred the slab gel contents to PVDF membranes and immunoblotted the contents with anti-PS-positive patient plasmas.
Dahlbäck et al. In the present study, as shown in Figure 4 , three immunobands were observed, suggesting anti-PS in the four patients bound to EGF1-2 (10-15 kDa fragment) and EGF3-4 (20-24 kDa fragment). PS activities in patients 1-4 were 46%, 38%, 62%, and 49%, respectively. Patients 1, 2, and 4 were deficient for PS activity. In other words, patients 1-4 were not deficient for total PS antigen (72%, 66%, 78%, and 70%, respectively). In control, PS activity and total PS antigen were 82% and 78%, respectively.
| Effects of Ca 2+ in immunoblot for anti-PS
PS was subjected to SDS-PAGE under reducing conditions. After we transferred the slab gel contents to PVDF membranes, the buff- PS incubated with lysyl endopeptidase was subjected to SDS-PAGE under non-reducing conditions. We then transferred the slab gel contents to PVDF membranes and immunoblotted the contents with anti-human EGF. As shown in Figure 6B , the three immunobands (approximately 10-15 kDa, 20-24 kDa, and 30 kDa) reported by Dahlbäck et al. 13, 20 were seen, suggesting that anti-human EGF bound to EGF1-2 (10-15 kDa fragment) and EGF3-4 (20-24 kDa fragment).
| Binding of polyclonal antibodies to EGF to PS
| Inhibition of anti-PS binding by anti-mouse EGF
PS was subjected to SDS-PAGE under non-reducing conditions. We then transferred the slab gel contents to PVDF membranes and incubated ). PS (3 μL of 600 μg/mL solution) was applied to each lane. Transfer to PVDF membrane was done for 20 minute at 0.1 amps. Membranes were blocked for 1.5 hours with 1% BSA in TBS at pH 7.3. Incubation with normal plasma (control) or anti-PS-positive patient plasmas (1/100) was done for 2 hours followed by three washes with 0.05% Tween 20/TBS. The membrane was exposed to horseradish peroxidase-conjugated polyclonal antibodies to human IgM for 1 hours. EGF, epidermal growth factor; PS, protein S; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PVDF, polyvinylidene difluoride; BSA, bovine serum albumin; TBS, Tris-buffered saline anti-human EGF recognized PS, the reactivity was not strong enough for competitive inhibition studies. Therefore, we used anti-mouse EGF.
| Binding of anti-PS to EGF
Recombinant mouse EGF, recombinant human EGF or human HB-EGF was subjected to SDS-PAGE. We then transferred the slab gel contents to PVDF membranes and immunoblotted the contents with anti-PS-positive patient plasmas. Figure 8 shows the binding of anti-PS to mouse EGF and human EGF, but not human HB-EGF. Among plasmas from 20 patients with recurrent pregnancy loss who were seropositive for anti-PS, 14 patients (70.0%) recognized mouse EGF.
| DISCUSSION
In the present study, we used thrombin to examine if anti-PS identi- It has been suggested that PS has an important role in multiple biological processes in addition to coagulation, including apoptosis, angiogenesis/vasculogenesis, and cancer progression. 21 PS accumulated around damaged placental trophoblastic cells in early and late pregnancy, indicating that there was a possibility that PS could protect or restore damaged villi and had physiological effects on the placenta. 22 Autoantibodies which recognize EGF-like domains in PS might be related to inhibition of angiogenesis and clearance of apoptotic cells during normal pregnancy.
Several studies focus on the effects of anti-PS on PS activity.
Two studies reported no evidence of PS activity inhibition by anti-PS. 8, 9 In contrast, Sorice et al. demonstrated the possibility of PS activity inhibition by anti-PS. 10 Whether anti-PS inhibits PS activity depends on the antigenic binding sites of anti-PS. In the present study, anti-PS recognized both the 10-15 kDa fragment comprising only EGF1-2 and the 20-24 kDa fragment comprising only EGF3-4 in the four patients. EGF1-2 are known to be directly involved in APC cofactor function. [13] [14] [15] [16] Three of the four patients whose anti-PS recognized EGF1-2 were in the low levels of PS activity. From these findings, anti-PS recognizing EGF1-2 may inhibit PS activity.
Given that EGF3-4 in PS are not directly involved in APC cofactor function, 18 we speculate that autoantibodies which recognize these EGF-like domains might be related to inhibition of angiogenesis other than coagulation.
In addition, anti-PS reactivities against PS under several Ca binding in PS are EGF2-4 in PS. 23 The study using recombinant human EGF-like domains in PS demonstrated that Ca 2+ induced conformational changes in these domains. 13, 23 These conformational changes ) was done for 2 hour followed by three washes with 0.05% Tween 20/TBS. The membrane was exposed to horseradish peroxidase-conjugated polyclonal antibodies to human IgG for 1 hour. EGF, epidermal growth factor; PS, protein S; SDS-PAGE, sodium dodecyl sulfatepolyacrylamide gel electrophoresis; FXII, factor XII; PVDF, polyvinylidene difluoride; BSA, bovine serum albumin; TBS, Trisbuffered saline; HB, heparin-binding
Protein S Intact factor XII Anti-human EGF Anti-human EGF Anti-HB-EGF Anti-HB-EGF CBB Anti-human EGF Anti-human EGF Anti-HB-EGF Anti-HB-EGF CBB ) of anti-mouse EGF or polyclonal antibodies to LGR in PS (residues 419 to 516) (anti-LGR) as a control was done for 1 hour. Thereafter, incubation with anti-PS-positive patient plasma (1/100) was done for 2 hour followed by three washes with 0.05% Tween 20/TBS. The membrane was exposed to horseradish peroxidase-conjugated polyclonal antibodies to human IgM for 1 hour. PS, protein S; EGF, epidermal growth factor; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PVDF, polyvinylidene difluoride; BSA, bovine serum albumin; TBS, Tris-buffered saline; LGR, a sex hormone-binding globulin-like domain containing two laminin G-like-domain-like repeats Protein S
Concentration
(mg/mL) Autoantibodies to EGF family proteins may inhibit uterine and placental angiogenesis crucial for the survival of embryo and fetus, leading to pregnancy loss.
Recently, our preliminary data suggested that anti-FXII autoantibodies (anti-FXII) in patients with recurrent pregnancy loss recognized EGF-like domains in FXII. Many of these anti-FXII also recognized PS. 28 FXII functions as a growth factor, which mediates cell signaling that leads to proliferation and stimulates angiogenesis. [29] [30] [31] Anti-FXII may inhibit these FXII functions.
In summary, our present study suggests that anti-PS in patients with recurrent pregnancy loss recognize EGF-like domains in PS.
Interestingly, anti-PS also recognized EGF family proteins. To date, thrombophilia has been especially focused on recurrent pregnancy loss; however, autoantibody-associated disruption of the EGF sys- 
